FBT
ALXN

First Bank & Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

First Bank & Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-61
Closed -$9K – 309
2017
Q3 		$9K Sell
61
-2,344
-97% -$318K 0.01% 226
2017
Q2 		$293K Sell
2,405
-1,177
-33% -$137K 0.25% 100
2017
Q1 		$434K Sell
3,582
-149
-4% -$19.2K 0.37% 74
2016
Q4 		$456K Buy
+3,731
New +$457K 0.42% 68

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

First Bank & Trust's ALXN Position: Q4 2017 in Review

First Bank & Trust sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 61 shares — an estimated $9K sold.

First Bank & Trust first reported a position in ALXN in Q4 2016 and held it in 4 quarters. The position peaked at $456K in Q4 2016. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • First Bank & Trust reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • First Bank & Trust sold 61 Alexion Pharmaceuticals shares in Q4 2017, an estimated $9K.
  • First Bank & Trust first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • First Bank & Trust's Alexion Pharmaceuticals position peaked at $456K in Q4 2016.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on First Bank & Trust's 13F filing for Q4 2017, filed 18 Jan 2018.